Form 4: Immunome Director Boosts Stake with 2,000 Share Purchase

Immunome Inc. Director Jean Jacques Bienaime acquired 2,000 shares of common stock through pre-planned transactions, increasing his direct ownership.

Summary

• Immunome Inc. Director Jean Jacques Bienaime purchased a total of 2,000 shares of the company's common stock.
• The purchases occurred on March 10, 2026, and March 11, 2026.
• On March 10, 2026, 1,000 shares were acquired at a price of $22.12 per share.
• On March 11, 2026, an additional 1,000 shares were acquired at a price of $21.55 per share.
• These transactions were executed under a Rule 10b5-1 pre-arranged trading plan.
• Following these acquisitions, Mr. Bienaime's direct beneficial ownership in Immunome Inc. increased to 38,415 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as insider buying indicates management confidence, though the transaction volume is not exceptionally large.

Positives

• A company director, Jean Jacques Bienaime, increased his personal stake in Immunome Inc. by purchasing 2,000 shares.
• Insider buying can signal management's confidence in the company's future prospects and valuation.
• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy.

Negatives

• No negative transactions (e.g., sales) were reported by the insider in this filing.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider buying, particularly from a director, can be a positive signal in the biotechnology sector, which often experiences high volatility and relies heavily on investor confidence in future pipeline developments and commercialization success. Such purchases suggest an internal belief in the company's long-term value, potentially counteracting broader market uncertainties or specific industry headwinds.

Comparison to Industry Standards

• Insider buying activity, especially from a director, is generally viewed favorably across all industries as it aligns management's interests with those of shareholders. For a biotech company like Immunome, where R&D success and regulatory approvals are critical, such a vote of confidence from an insider can be particularly impactful compared to companies in more stable, mature industries.
• While the volume of 2,000 shares is modest, the consistent buying over two days at slightly different price points indicates a deliberate accumulation strategy, which is a stronger signal than a single, isolated purchase.

Stakeholder Impact

• Shareholders: May view the director's increased stake as a positive sign of confidence, potentially leading to increased investor interest and a positive impact on share price.
• Employees: Could interpret the insider buying as a sign of stability and positive future prospects for the company.

Key Dates

Recommendation

While insider buying is a positive indicator of management confidence, the relatively modest volume of shares purchased by the director, without additional significant news or financial disclosures, suggests a 'hold' recommendation. It reinforces existing positions but may not be a strong enough catalyst for a 'buy' without further fundamental analysis or market-moving news.

Keywords

Immunome Inc., IMNM, Insider Buying, Director Purchase, Stock Acquisition, Form 4, SEC Filing, Jean Jacques Bienaime, Biotech, Pharmaceuticals